• Policy
• Tagrisso’s succeeds in RSA renewal… 3% price cut per dose
• by Kim, Jung-Ju Feb 18, 2022 05:55am

• Company
• AstraZeneca wins second trial on ‘Forxiga substance patent'
• by Kim, Jin-Gu Feb 18, 2022 05:55am

• Company
• The industry is worried about the spread of Omikron
• by Kim, Jin-Gu Feb 18, 2022 05:55am

• Policy
• What is the pledge of the presidential candidates?
• by Lee, Jeong-Hwan Feb 18, 2022 05:54am

• Company
• The development of next lung cancer txs is in full swing
• by Feb 17, 2022 05:53am

• Opinion
• [Reporter’s View] Why set deadlines in pricing negotiations
• by Eo, Yun-Ho Feb 17, 2022 05:53am

• Company
• Seqirus “to supply next-gen influenza vaccine” in Korea
• by Feb 17, 2022 05:53am

• Policy
• Rybrevant has been approved in Korea
• by Lee, Tak-Sun Feb 17, 2022 05:52am

• Policy
• Revised the method of Rx notes for health functional foods
• by Lee, Jeong-Hwan Feb 17, 2022 05:52am

• Company
• Roche's Polivy can be prescribed at Big 5 hospitals
• by Eo, Yun-Ho Feb 16, 2022 05:51am